1,3-Dioxane Modulators for Integrated Stress Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that can effectively modulate the integrated stress response pathway with improved pharmacokinetic properties for the treatment of related diseases such as cancer and neurodegenerative disorders, addressing issues of activity, solubility, selectivity, and reduced side effects.
Innovation Solution
Development of 1,3-dioxane derivatives with specific substituents that act as modulators of the integrated stress response pathway, including compounds of formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, and stereoisomers, which target the eIF2 complex to regulate protein synthesis and stress response gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing modulators of the integrated stress response pathway are used, then the pathway can be modulated, but pharmacokinetic properties such as solubility, selectivity, and side effects are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of dioxane derivatives, including variations in substituents at different positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 groups), to optimize pharmacokinetic properties such as solubility, metabolic stability, and selectivity while reducing side effects
Solution Approach 2:
The patent employs local quality by introducing specific functional groups and substituents at particular positions on the dioxane core structure (such as fluorine atoms, hydroxyl groups, alkoxy chains, and aromatic rings) to enhance specific pharmacokinetic properties without compromising overall molecular function
2Reliability
If compounds with improved pharmacokinetic properties are developed, then treatment efficacy may be enhanced, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into a core dioxane structure with separate, modular substituent groups (R1-R10) that can be independently optimized and synthesized, then assembled through standardized coupling reactions to create final compounds with desired pharmacokinetic properties
Solution Approach 2:
The patent employs universality by designing a platform dioxane core structure that can serve multiple therapeutic indications (cancer, neurodegenerative disorders, inflammatory conditions) through systematic variation of substituents, allowing a single synthesis framework to generate compounds for diverse applications
Data Source
AI summary
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.